Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis

Abstract

Rituximab is beneficial when prescribed outside of a trial setting. Response to treatment and relapse is similar regardless of infusion number. Rituximab without cyclophosphamide may result in a shorter time to relapse supporting combination of these therapies.